 Jennifer Trujillo
Concepts (168)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Education, Pharmacy | 16 | 2026 | 120 | 6.730 |
Why?
| | Students, Pharmacy | 14 | 2026 | 96 | 4.120 |
Why?
| | Hypoglycemic Agents | 21 | 2025 | 1399 | 3.460 |
Why?
| | Diabetes Mellitus, Type 2 | 22 | 2025 | 2588 | 3.180 |
Why?
| | Educational Measurement | 11 | 2026 | 326 | 2.690 |
Why?
| | Glucagon-Like Peptides | 5 | 2020 | 71 | 1.670 |
Why?
| | Curriculum | 11 | 2026 | 1070 | 1.470 |
Why?
| | Glucagon-Like Peptide 1 | 6 | 2018 | 149 | 1.460 |
Why?
| | Peptides | 7 | 2018 | 998 | 1.330 |
Why?
| | Artificial Intelligence | 2 | 2026 | 381 | 1.320 |
Why?
| | Receptors, Glucagon | 3 | 2015 | 27 | 1.280 |
Why?
| | Insulin Glargine | 4 | 2022 | 88 | 1.200 |
Why?
| | Hypoglycemia | 6 | 2022 | 479 | 1.060 |
Why?
| | Insulin | 8 | 2022 | 2512 | 0.880 |
Why?
| | Education, Distance | 1 | 2025 | 59 | 0.860 |
Why?
| | Writing | 1 | 2026 | 101 | 0.860 |
Why?
| | Pharmacists | 4 | 2026 | 258 | 0.830 |
Why?
| | Blood Glucose | 9 | 2020 | 2341 | 0.740 |
Why?
| | Osteoarthritis | 1 | 2025 | 200 | 0.730 |
Why?
| | Teaching | 2 | 2015 | 237 | 0.710 |
Why?
| | Liraglutide | 4 | 2016 | 32 | 0.700 |
Why?
| | Schools, Pharmacy | 4 | 2026 | 48 | 0.690 |
Why?
| | Immunoglobulin Fc Fragments | 3 | 2020 | 41 | 0.690 |
Why?
| | Glucagon-Like Peptide-2 Receptor | 5 | 2018 | 16 | 0.650 |
Why?
| | Anti-Obesity Agents | 3 | 2016 | 67 | 0.640 |
Why?
| | Glucagon-Like Peptide-1 Receptor | 5 | 2020 | 88 | 0.610 |
Why?
| | Glucagon | 1 | 2020 | 114 | 0.580 |
Why?
| | Metformin | 2 | 2020 | 329 | 0.570 |
Why?
| | Recombinant Fusion Proteins | 3 | 2020 | 666 | 0.570 |
Why?
| | Emergency Treatment | 1 | 2020 | 123 | 0.570 |
Why?
| | Medication Therapy Management | 1 | 2019 | 72 | 0.550 |
Why?
| | Weight Loss | 7 | 2025 | 858 | 0.540 |
Why?
| | Societies, Pharmaceutical | 2 | 2016 | 14 | 0.530 |
Why?
| | Hyperglycemia | 2 | 2014 | 379 | 0.520 |
Why?
| | Patient Education as Topic | 4 | 2018 | 777 | 0.510 |
Why?
| | Humans | 44 | 2026 | 145474 | 0.480 |
Why?
| | Gastrointestinal Diseases | 1 | 2018 | 221 | 0.470 |
Why?
| | Education, Pharmacy, Graduate | 2 | 2017 | 13 | 0.430 |
Why?
| | Drugs, Investigational | 1 | 2014 | 31 | 0.420 |
Why?
| | Problem-Based Learning | 2 | 2017 | 97 | 0.410 |
Why?
| | Drug Combinations | 4 | 2018 | 396 | 0.390 |
Why?
| | Body Weight | 4 | 2020 | 971 | 0.380 |
Why?
| | Health Literacy | 1 | 2015 | 185 | 0.370 |
Why?
| | Peer Review | 1 | 2012 | 47 | 0.350 |
Why?
| | Drug Administration Schedule | 3 | 2020 | 782 | 0.350 |
Why?
| | Clinical Trials, Phase III as Topic | 3 | 2022 | 116 | 0.350 |
Why?
| | Patient-Centered Care | 1 | 2016 | 547 | 0.340 |
Why?
| | Interpersonal Relations | 1 | 2014 | 397 | 0.330 |
Why?
| | Learning | 1 | 2015 | 443 | 0.320 |
Why?
| | Diet Records | 1 | 2009 | 89 | 0.290 |
Why?
| | Pancreatitis | 1 | 2010 | 146 | 0.290 |
Why?
| | Faculty, Medical | 1 | 2012 | 303 | 0.280 |
Why?
| | Cultural Competency | 1 | 2009 | 88 | 0.280 |
Why?
| | Drug Interactions | 1 | 2009 | 405 | 0.270 |
Why?
| | Cardiovascular Diseases | 2 | 2017 | 2187 | 0.260 |
Why?
| | Attitude of Health Personnel | 3 | 2015 | 1193 | 0.250 |
Why?
| | Communication | 4 | 2016 | 975 | 0.250 |
Why?
| | Empathy | 1 | 2009 | 181 | 0.250 |
Why?
| | Diabetes Mellitus | 2 | 2020 | 1097 | 0.240 |
Why?
| | Peer Group | 1 | 2008 | 253 | 0.240 |
Why?
| | Program Evaluation | 3 | 2017 | 943 | 0.240 |
Why?
| | Clinical Protocols | 1 | 2008 | 280 | 0.240 |
Why?
| | Clinical Trials as Topic | 3 | 2020 | 1061 | 0.230 |
Why?
| | School Admission Criteria | 1 | 2026 | 35 | 0.230 |
Why?
| | Accreditation | 1 | 2026 | 101 | 0.230 |
Why?
| | Competency-Based Education | 1 | 2026 | 81 | 0.220 |
Why?
| | Obesity | 2 | 2016 | 3116 | 0.220 |
Why?
| | Drug Therapy, Combination | 2 | 2020 | 1044 | 0.220 |
Why?
| | Faculty, Pharmacy | 1 | 2024 | 20 | 0.210 |
Why?
| | Family Practice | 1 | 2008 | 407 | 0.200 |
Why?
| | Drug Utilization Review | 1 | 2004 | 61 | 0.200 |
Why?
| | Spironolactone | 1 | 2004 | 40 | 0.200 |
Why?
| | Venoms | 2 | 2015 | 22 | 0.200 |
Why?
| | Mineralocorticoid Receptor Antagonists | 1 | 2004 | 69 | 0.190 |
Why?
| | Gastric Inhibitory Polypeptide | 1 | 2022 | 13 | 0.190 |
Why?
| | Reproducibility of Results | 2 | 2026 | 3413 | 0.170 |
Why?
| | Injections, Subcutaneous | 2 | 2014 | 170 | 0.170 |
Why?
| | Internet | 1 | 2025 | 689 | 0.160 |
Why?
| | Administration, Intranasal | 1 | 2020 | 94 | 0.150 |
Why?
| | Patient Compliance | 1 | 2004 | 587 | 0.150 |
Why?
| | Professional Role | 2 | 2019 | 169 | 0.150 |
Why?
| | Delayed-Action Preparations | 1 | 2020 | 189 | 0.150 |
Why?
| | Nausea | 1 | 2020 | 112 | 0.150 |
Why?
| | Cardiovascular System | 1 | 2020 | 138 | 0.140 |
Why?
| | Postprandial Period | 1 | 2018 | 114 | 0.130 |
Why?
| | Insulin, Long-Acting | 1 | 2017 | 65 | 0.130 |
Why?
| | Commission on Professional and Hospital Activities | 1 | 2017 | 4 | 0.130 |
Why?
| | Canagliflozin | 1 | 2017 | 11 | 0.130 |
Why?
| | Administration, Oral | 1 | 2020 | 866 | 0.130 |
Why?
| | Internship and Residency | 1 | 2008 | 1267 | 0.120 |
Why?
| | Health Knowledge, Attitudes, Practice | 2 | 2016 | 1419 | 0.120 |
Why?
| | Perception | 1 | 2019 | 378 | 0.120 |
Why?
| | Glucosides | 1 | 2017 | 56 | 0.120 |
Why?
| | Professional Practice | 1 | 2016 | 57 | 0.120 |
Why?
| | Treatment Outcome | 3 | 2020 | 11772 | 0.120 |
Why?
| | Benzhydryl Compounds | 1 | 2017 | 81 | 0.120 |
Why?
| | Surveys and Questionnaires | 3 | 2019 | 6066 | 0.110 |
Why?
| | Drug Approval | 1 | 2015 | 93 | 0.110 |
Why?
| | Self Care | 1 | 2018 | 390 | 0.110 |
Why?
| | Self-Management | 1 | 2018 | 202 | 0.110 |
Why?
| | Sitagliptin Phosphate | 1 | 2015 | 31 | 0.110 |
Why?
| | Counseling | 1 | 2018 | 400 | 0.110 |
Why?
| | United States Food and Drug Administration | 1 | 2015 | 208 | 0.110 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2015 | 1747 | 0.100 |
Why?
| | Pyrazines | 1 | 2015 | 94 | 0.100 |
Why?
| | Thiazolidinediones | 1 | 2015 | 139 | 0.100 |
Why?
| | Disease Management | 1 | 2018 | 653 | 0.100 |
Why?
| | Triazoles | 1 | 2015 | 187 | 0.100 |
Why?
| | United States | 4 | 2026 | 16098 | 0.090 |
Why?
| | Pilot Projects | 2 | 2008 | 1891 | 0.090 |
Why?
| | Community Pharmacy Services | 1 | 2012 | 46 | 0.090 |
Why?
| | Comprehension | 1 | 2014 | 186 | 0.090 |
Why?
| | Educational Status | 1 | 2014 | 466 | 0.090 |
Why?
| | Adult | 6 | 2022 | 40777 | 0.090 |
Why?
| | Retrospective Studies | 4 | 2022 | 17291 | 0.090 |
Why?
| | Pharmacy Service, Hospital | 1 | 2012 | 89 | 0.090 |
Why?
| | Incidence | 1 | 2018 | 2923 | 0.080 |
Why?
| | Feedback | 1 | 2012 | 180 | 0.080 |
Why?
| | Algorithms | 1 | 2019 | 1845 | 0.080 |
Why?
| | Comorbidity | 1 | 2015 | 1661 | 0.080 |
Why?
| | Heart Failure | 1 | 2004 | 2326 | 0.080 |
Why?
| | Health Care Costs | 3 | 2022 | 425 | 0.080 |
Why?
| | Continuity of Patient Care | 1 | 2012 | 297 | 0.080 |
Why?
| | Male | 7 | 2022 | 72842 | 0.080 |
Why?
| | Data Collection | 1 | 2012 | 640 | 0.070 |
Why?
| | Female | 7 | 2022 | 78844 | 0.070 |
Why?
| | Patient Safety | 1 | 2012 | 356 | 0.070 |
Why?
| | Clinical Competence | 1 | 2016 | 1243 | 0.070 |
Why?
| | Observer Variation | 1 | 2008 | 357 | 0.070 |
Why?
| | Professional-Patient Relations | 1 | 2009 | 147 | 0.070 |
Why?
| | Boston | 1 | 2008 | 93 | 0.070 |
Why?
| | Advisory Committees | 1 | 2008 | 229 | 0.060 |
Why?
| | Acute Disease | 1 | 2010 | 1036 | 0.060 |
Why?
| | Quality Assurance, Health Care | 1 | 2008 | 342 | 0.060 |
Why?
| | Concurrent Review | 1 | 2004 | 2 | 0.050 |
Why?
| | Hospitals, Teaching | 1 | 2004 | 120 | 0.050 |
Why?
| | Massachusetts | 1 | 2004 | 180 | 0.050 |
Why?
| | Hospitals, Urban | 1 | 2004 | 142 | 0.050 |
Why?
| | Guideline Adherence | 1 | 2008 | 586 | 0.050 |
Why?
| | Animals | 1 | 2025 | 38030 | 0.050 |
Why?
| | Aged | 4 | 2022 | 26153 | 0.040 |
Why?
| | Patient Care Team | 1 | 2008 | 696 | 0.040 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2014 | 3922 | 0.030 |
Why?
| | Hospitalization | 1 | 2008 | 2460 | 0.030 |
Why?
| | Analysis of Variance | 1 | 2019 | 1300 | 0.030 |
Why?
| | Aged, 80 and over | 2 | 2012 | 8333 | 0.030 |
Why?
| | Middle Aged | 3 | 2012 | 36215 | 0.030 |
Why?
| | Phentermine | 1 | 2016 | 14 | 0.030 |
Why?
| | Benzazepines | 1 | 2016 | 35 | 0.030 |
Why?
| | Severity of Illness Index | 1 | 2004 | 2930 | 0.030 |
Why?
| | Bupropion | 1 | 2016 | 48 | 0.030 |
Why?
| | Fructose | 1 | 2016 | 132 | 0.030 |
Why?
| | Prospective Studies | 1 | 2008 | 8057 | 0.030 |
Why?
| | Motivation | 1 | 2019 | 600 | 0.030 |
Why?
| | Naltrexone | 1 | 2016 | 115 | 0.030 |
Why?
| | Cough | 1 | 2014 | 124 | 0.020 |
Why?
| | Forced Expiratory Volume | 1 | 2014 | 450 | 0.020 |
Why?
| | Administration, Inhalation | 1 | 2014 | 571 | 0.020 |
Why?
| | Pharmacology, Clinical | 1 | 2012 | 9 | 0.020 |
Why?
| | Medication Reconciliation | 1 | 2012 | 32 | 0.020 |
Why?
| | Medical Informatics | 1 | 2012 | 99 | 0.020 |
Why?
| | Health Personnel | 1 | 2017 | 754 | 0.020 |
Why?
| | Creatinine | 1 | 2012 | 515 | 0.020 |
Why?
| | Drug Monitoring | 1 | 2012 | 401 | 0.020 |
Why?
| | Colorado | 1 | 2017 | 4553 | 0.020 |
Why?
| | Quality Improvement | 1 | 2012 | 1295 | 0.010 |
Why?
| | Interprofessional Relations | 1 | 2006 | 275 | 0.010 |
Why?
| | Cohort Studies | 1 | 2012 | 6013 | 0.010 |
Why?
|
|
Trujillo's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|